Skip to content
Study details
Enrolling now

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Teva Branded Pharmaceutical Products R&D LLC
NCT IDNCT06052267ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

2,196

Study length

about 2.9 years

Ages

4+

Locations

157 sites in AL, AZ, CA +30

About this study

Researchers are testing whether a fixed dose combination of fluticasone propionate and albuterol sulfate, given as an inhaler, can help prevent severe asthma attacks. The trial will last for up to 35 months and involve adults and children with asthma.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Albuterol sulfate
  • 2.Take TEV-56248
PhasePhase 3
DrugAlbuterol sulfate
Routeinhaled

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

Respiratory System Agent (Adrenergic beta2-Agonists)

Drug routes

inhaled

Endpoints

Secondary: Composite Responders Based on Asthma Quality of Life Questionnaire + 12 (AQLQ+12) or Pediatric AQLQ (PAQLQ), Number of Participants Who Withdrew From the Trial Due to Treatment-Emergent Adverse Events, Number of Participants with at Least One Adverse Event, Number of Participants with at Least One Serious Adverse Event

Body systems

Respiratory